Helus Pharma (Nasdaq: HELP), the commercial operating name of Cybin Inc., announced the addition of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board to support advancement of its novel serotonergic agonists pipeline.
Key takeaways
Helus Pharma added Dr. Robert Langer, renowned biotechnology leader and Moderna co-founder, to its Scientific Advisory Board.
Dr. Stephen Brannan, former Chief Medical Officer at Karuna Pharmaceuticals and Takeda Neuroscience lead, joins the Scientific Advisory Board.
Board chaired by Dr. Freda Lewis-Hall, ex-Pfizer Chief Medical Officer, focusing on clinical development and regulatory strategy.
Addition supports pipeline including HLP003 (Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation) and HLP004 (Phase 2 for generalized anxiety disorder).
Eric So, interim CEO, highlighted their expertise in translating science into therapies and advancing CNS programs.